Researchers at the University of Helsinki identified a molecule called BT13 that potentially can increase levels of dopamine.

This whitepaper assesses the current state of the large molecule sector, and how it may be able to learn from the small molecule industry in terms of its supply chain support infrastructure, as well as its acquisition of staff and the adoption of PAT.